Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of FANG™ Autologous Tumor Cell Vaccine in Advanced Melanoma

NCT01453361 is registered in ClinicalTrials.gov with Gradalis, Inc. as lead sponsor.

NCT NCT01453361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01453361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of FANG™ Autologous Tumor Cell Vaccine in Advanced Melanoma
Lead sponsor
Gradalis, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2011
Completion date
March 22, 2016
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma